- SELECTED PRESENTATION
- Open Access
Discrepancies between European countries and USA and Canada in the availability of triptans and in their licensed clinical properties
© Springer-Verlag Italia 2003
Triptans are presently a milestone in the treatment of migraine patients. Because of their effectiveness and safety, they have radically improved migraine treatment but their use has meant a substantial increase in spending for medicines. We compared available pharmaceutical forms, pack sizes, indications and dosages of triptans as listed in the summary of product characteristics of eight countries. We found that several differences exist between countries in the presentations of the triptans and in their licensing.